A Comprehensive Overview on BHF PROTECT TAVI & Cerebral Embolic Protection
Published: 12 June 2023
5m 29sPart 2 | Session 1 Episode 1: Stroke Overview and CEP Consideration in TAVI
4m 57sPart 2 | Session 2 Episode 2: Reflecting on PROTECTED TAVR
7m 9sPart 2 | Session 3 Episode 3: Overview of the BHF PROTECT TAVI
7m 58sPart 2 | Session 4 Episode 4: The Current Status and Future of CEP
In this exclusive interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) speaks with Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK), Principal Investigator of the BHF PROTECT TAVI trial. This highly anticipated trial aims to provide groundbreaking insights into the field of Cerebral Embolic Protection (CEP) in TAVI.
In this interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) and Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) delve into the unique aspects of the BHF PROTECT TAVI trial, highlighting its distinguishing features compared to previous studies. They provide a comprehensive overview of the trial's current progress, shedding light on its outcomes, learnings, and potential clinical implications.
Moreover, the interview focuses on why the BHF PROTECT TAVI trial holds immense value for future considerations of CEP in TAVI. Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) and Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) discuss the potential impact of this trial on daily clinical practice, particularly in assessing stroke risk during TAVI procedures.
Furthermore, the interview addresses the significance of CEP in TAVI patients, emphasising the potentially life-altering consequences of stroke and its associated costs. By exploring the current status of CEP and its impact on patients, this interview provides a comprehensive update on the subject.
- Identify and analyse the main outcomes, learnings, and clinical implications of the PROTECTED TAVR trial
- Understand the design of the BHF PROTECT TAVI trial, including its differences from previous studies and assess its current status and progress
- Recognise the potential significance of BHF PROTECT TAVI in assessing daily clinical practice considerations for stroke risk in TAVI
- Assess the current status of Cerebral Embolic Protection in TAVI, its impact on patients undergoing TAVI procedures, and the associated cost implications
- Clinical Cardiologists
- Interventional Cardiologists
- Cardiac Surgeons
More from this programme
Watch the full interview A Comprehensive Overview on BHF PROTECT TAVI & Cerebral Embolic Protection
Dr Tessel Vossenberg studied Medicine at the University of Amsterdam. Dr Tessel Vossenberg is particularly interested in complex coronary interventions, and structural heart diseases interventions such as mitral valve, tricuspid valve and aortic valve (TAVI) interventions. In addition, she has specialised in coronary physiology and microvascular coronary artery disease.
Prof Rajesh Kharbanda, Consultant Cardiologist in Oxford, graduated from Edinburgh Medical School in 1991, and has trained and worked in the speciality of cardiology in London, Cambridge, Toronto (Canada).